Mundipharma
Nimisha Joshi is an experienced finance professional currently serving as the Operational Excellence and Projects Lead at Mundipharma since May 2021, with previous roles including Finance Business Partner for COGs & GM and Global Support Functions. Prior to Mundipharma, Nimisha held the position of Finance Business Partner at LCR Property from June 2020 to April 2021 and worked at Kuoni Global Travel Services from September 2016 to March 2020 as Business Partner for Global Operations & MICE. Early career highlights include various finance roles at New Look, The White Company, Carlson Wagonlit Travel, Next Group PLC, and West Bromwich Building Society. Nimisha earned a BSc (Hons) in Business and Management from Aston University and is qualified through The Chartered Institute of Management Accountants.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.